Zoetis Inc. is a pharmaceutical company particularly engaged in treatments for pets and livestock. It researches, develops, manufactures, and markets medicine, vaccines, and diagnostic products, as well as biodevices, genetic tests, services, and animal health solutions for pets and companion animals, farm animals, and precision livestock farming.
10 Sylvan Way, Parsippany, NJ 07054
CategoryBiotech & Pharmaceuticals
We monitor potential impacts of climate change and evaluate efforts to combat climate change on our operations and strategy. We consider the potential impact climate change could have on our globally diverse network of manufacturing sites, Veterinary Medical Research and Development (VMRD) locations, and customer distribution centers. We have identified climate change as one factor with the potential to negatively impact our customers’ operations, particularly those in the livestock industry, through climate-related impacts such as increased air and water temperatures, rising water levels and increased incidence of disease in livestock. If such events affect our customers’ businesses, they may purchase fewer Zoetis products, and our revenues may be negatively impacted. In addition, we have identified the ongoing risk of new or expanded laws and regulations, including those related to environmental, health and safety, on our business, and this risk incorporates any legal and regulatory changes aimed at decreasing or delaying global warming. These risks are part of our enterprise risk management program described below. At Zoetis, our business purpose is also a social purpose. The medicines, vaccines, products and services we develop, manufacture and deliver play a key role in supporting veterinarians, pet owners and food producers in keeping the animals in their care healthy. This support contributes to lifelong companionship between owners and their pets and helps to ensure a safe and sustainable food supply for the world. Given this role, our industry and company were deemed an essential business by governments around the world as the COVID-19 crisis spread. In the face of significant challenges, our colleagues continued to deliver on our mission to support our customers and the animals in their care. I am incredibly proud of all our colleagues for this work and their commitment to making a meaningful contribution to animal and human health in the face of this crisis.Our Board of Directors has determined that oversight of our overall sustainability program is most effective at the Board level. The Board is increasingly focused on our sustainability strategy as we have designated sustainability as one of our strategic priorities. The Board will continue to provide guidance regarding sustainability goals and the overall sustainability strategy and will monitor our progress in environmental, social and governance areas, including climate change, in order to enable sustainable growth over the long term. The Board receives regular updates on our enterprise risk management program, including risks related to climate change. The Board also exercises its oversight of environmental, social and governance issues through its committees and receives regular updates from its committees regarding their respective areas of oversightZoetis is a leader in animal health. Its diverse portfolio of animal health products contributes to its financial stability. Zoetis generates revenue from the sales of veterinary pharmaceuticals, vaccines, and diagnostics. The company’s focus on animal health addresses diverse healthcare needs for pets and livestock, sustaining its financial performance.The Zoetis Code of Conduct mandates that all promotional materials and communications must be accurate, not misleading, and compliant with all applicable legal and regulatory standards, including any applicable standards addressing off-label promotion, substantiation, scientific rigor and fair balance. Colleagues in sales, marketing, veterinary medical services and regulatory functions are trained on, and must comply with, local or regional policies with respect to labeling, promotional programs, product samples and other related topics. Regulatory review committees are used on a regional basis to review and approve marketing and promotional materials prior to their use. Compliance with policy is subject to internal audits, and policy violations may result in disciplinary actions, up to and including colleague termination.